Warabi Shibata

Sarcopenia affects the outcomes and tolerability in patients with interstitial lung disease receiving nintedanib: a retrospective study

Nintedanib is approved for various interstitial lung diseases (ILDs). Although sarcopenia, which is characterized by a loss of skeletal muscle mass, is known to affect the outcome of ILD, the outcome of patients with sarcopenia receiving nintedanib remains unclear. Fifty-six pati...